Brief: Tetra Bio-Pharma's Qixleef On Track After Type C Meeting With U.S. FDA
17/03/2022 10:31
March 17 (Reuters) - Tetra Bio Pharma Inc TBP.TO :
* TETRA BIO-PHARMA'S QIXLEEF™ ON TRACK AFTER TYPE C MEETING
WITH
U.S. FDA
* TETRA BIO - TYPE C MEETING WITH FDA PROVIDES GUIDANCE TO
STRENGTHEN QIXLEEF NONCLINICAL AND TOXICOLOGICAL DATA PACKAGE
FOR MARKETING APPROVAL
Source text for Eikon: ID:nPn6trJta
Further company coverage: TBP.TO
Recent news on Tetra Bio Pharma
See all newsBrief: Tetra Bio Receives A Second Clarifax From Health Canada Regarding Reduvo Risk Management Plan
Brief: Tetra Bio-Pharma Announces Results Of Artificial Intelligence Study Of ARDS-003 Combined With Favipiravir
Brief: Tetra Bio-Pharma Provides Update On Patent Applications For Novel Therapeutic Ards-003
Brief: Tetra Bio-Pharma Provides Update On Patent Applications For Novel Therapeutic Ards-003
Brief: Tetra And Prepaire Jointly Apply To Barda For Funding